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The DCC (deleted in colon carcinoma) gene, a putative tumour
suppressor gene, spans nearly 1.35 megabases with at least 29
exons and is located within the 18q21.3 region (Fearon et al,
1990). The cDNA predicts a 1447-amino acid transmembrane
protein with four immunoglobulin-like and six fibronectin III-like
domains, showing high homology to the neural cell adhesion
molecule family of cell surface proteins (Cho et al, 1994). In
normal mammalian tissues, abundant expression of DCC mRNA
and protein is common in the central and peripheral nervous
system, as well as most epithelial tissues (Hedrick et al, 1994;
Reale et al, 1994). Full-length but not truncated DCC was found to
inhibit tumorigenicity in a human squamous cell carcinoma cell
line lacking endogenous DCC expression (Klingelhutz et al,
1995), and reduced or missing DCC expression has been demon-
strated in a variety of human malignancies, including prostate,
gastric and oesophageal carcinomas (Gao et al, 1993; Huang et al,
1992; Uchino et al, 1992).
The ovarian epithelial carcinoma is clinically one of the most
important tumours of the female reproductive system, since
approximately 75% of patients are diagnosed at an advanced stage.
Recent molecular studies of ovarian neoplasias have demonstrated
the presence of several genetic alterations, such as CD44 abnor-
malities, c-erbB-2 amplification, and K-ras mutations (Slamon et
al, 1989; Zeimet et al, 1997; Mandai et al, 1998). Although DCC
expression has been investigated using a limited number of
ovarian carcinoma cases (Enomoto et al, 1995), any association
with tumour progression or survival is still unclear. In addition,
little is known about changes in benign and premalignant ovarian
tumours.
The p53 gene is also a tumour suppressor gene, and a high inci-
dence of gene mutations leading to non-functional protein over-
expression has been demonstrated in various types of human
malignant tumours, including ovarian carcinomas (Herod et al,
1996). However, there have been no reports concerning any rela-
tion between p53 and DCC alterations in ovarian tumours.
In this study, we investigated benign, premalignant and malig-
nant ovarian neoplasias to clarify the possible role of DCC gene
expression in tumour development and progression, using
immunohistochemistry and a combination of the reverse transcrip-
tion polymerase chain reaction (RT-PCR) assay with Southern blot
hybridization (SBH). The results were compared with p53 expres-
sion, several prognostic factors and survival.
MATERIALS AND METHODS
Cases
A total of 124 cases of ovarian carcinomas, surgically resected at
Kitasato University Hospital during the period from 1992 to 1998,
were investigated, along with 41 low malignant potential (LMP)
tumours and 55 cystadenomas. The ages of the patients ranged
from 26 to 83 years, with a mean of 53.6.
All cases underwent oophorectomy with or without hysterec-
tomy. All tissues were routinely fixed in 10% formalin and
processed for embedding in paraffin wax. Histological diagnoses
were performed according to the criteria of the International
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international system. The tumour cases investigated comprised 51
serous, 23 mucinous, 13 endometrioid and 37 clear cell ovarian
carcinomas, as well as 12 serous and 29 mucinous LMP tumours,
and 22 serous and 33 mucinous cystadenomas. Data for clinico-
pathological factors, including histological grade, FIGO stage and
lymph node status, were also examined for comparison with the
results of immunohistochemistry.
Of 124 ovarian carcinoma cases, 106 could be analysed for their
outcome after surgery, with a mean follow-up time of 22.7 months
(range 1–75 months). Some cases had received platinum-based
chemotherapy after primary surgery.
Twenty-six ovarian carcinoma (12 serous, two endometrioid,
five mucinous and seven clear cell), five LMP (one serous and
four mucinous), eight cystadenoma (two serous and six muci-
nous), and seven normal ovarian tissue samples were snap-frozen
in liquid nitrogen for DCC mRNA analysis.
Immunohistochemistry
Immunohistochemistry was performed using a combination of
microwave-oven heating and standard streptavidin–biotin–peroxi-
dase complex (LSAB kit, Dako, Copenhagen, Denmark) methods.
Briefly, slides were heated in 10 mM citrate buffer (pH 6.0) for six
5-min cycles for DCC proteins, as described by Shibata et al
(1996), and three 5-min cycles for p53 proteins, using a
microwave oven and then incubated overnight at 4°C with
optimum dilutions of primary antibodies. The antibodies used
were anti-human DCC monoclonal antibody (clone G97-449,
´100 dilution, Pharmingen, San Diego, CA, USA) and anti-p53
protein (DO-7) mouse monoclonal antibody (´500 dilution,
Novocastra Lab. Ltd, Newcastle, UK). To confirm the specificity
of binding, normal mouse serum (´500 dilution) was supplied
instead of primary antibody as a negative control.
Evaluation for DCC and p53 immunoreactivity
Scoring of the DCC immunohistochemistry results was achieved
as previously reported (Sinicrope et al, 1995; Saegusa et al, 1996).
Briefly, based on the percentages of immunopositive epithelial
cells among the totals of normal or neoplastic cells on a slide
section, subdivision was made into five categories as follows: 0,
all negative; 1, < 10% positive cells; 2, 10–30%; 3, 30–50%; and
4, > 50%. The immunointensity was also subclassified into four
groups as follows: 0, negative; 1+, weak; 2+, moderate; and 3+,
strong. Immunoreactivity scores were generated by multiplication
of the values for the two parameters. As positive controls, normal
colonic epithelium for DCC and a p53-positive colorectal carci-
noma for p53 were used.
With regard to p53, the staining results were considered to be
positive when more than 30% of the totals of neoplastic cells
showed nuclear staining (Baas et al, 1994).
Reverse transcription-polymerase chain reaction
Total cellular RNA was extracted from 40 neoplastic and seven
normal ovarian frozen tissues using Isogen (Nippon Gene Co.,
Tokyo, Japan) and cDNAs were synthesized from 5 mg of total
RNA using RAV-2 reverse transcriptase (Takara, Shiga, Japan) in
the presence of random primers (Takara) and a ribonuclease
inhibitor (Takara) in a 20 ml reaction volume at 42°C for 60 min.
One microlitre of cDNA solution was amplified by Taq poly-
merase (Takara) in a volume of 10 ml. For detection of DCC
mRNA expression in exons 6–7, primers used were 5¢- TTC-
CGCCATGGTTTTTAAATCA-3¢ (sense) and 5¢-AGCCT-
CATTTTCAGCCACACA-3¢ (anti-sense), as reported by Fearon
et al (1990). For analysis of alternative splicing in the extracellular
domain (exon 17), the primers used were DCK2834S, 5¢-CCCA-
GACTAACTGCATCATCATGAG-3¢ (sense), and DCK3151A,
5¢-CACCTACTGGTGGGAGCAT-3¢ (anti-sense), described by
Reale et al (1994). The PCR procedure was performed with 35
cycles of denaturation at 94°C for 0.5 min, annealing at 55°C for 
1 min and extension at 72°C for 1 min, with a final extension time
of 7 min. As a negative control, water was supplied instead 
of template DNA for each examination. To examine the quality
and quantity of the synthesized cDNA, the b-actin specific primers
(sense, 5¢-TGCTATCCAGGCTGTGCTAT-3¢ and anti-sense, 5¢-
GATGGAGTTGAAGGTAGTTT-3¢) were also applied for ampli-
fication (Horstmann et al, 1997). PCR assays were performed in
duplicate or triplicate.
Southern blot hybridization
A 10 ml aliquot of each PCR reaction mixture was electrophoresed
in a 3.0% agarose gel and transferred to a Hybond N nylon
membrane (Amersham, Tokyo, Japan). After prehybridization
using DIG Easy Hyb (Boehringer Mannheim, Tokyo, Japan) solu-
tion, filters were hybridized overnight with each digoxigenin-
labelled exon-specific probe, which corresponded to internal sites
between primer sets used. The sequences of oligonucleotide
probes for DCC exon 6/7, DCC exon 17, and b-actin were as
follows: probe DCC exon 6/7 (5¢-AATTGGATGAAGAATGGA-
GATGTGGTCATT-3¢, encoding nucleotides 1087–1116 in the
cDNA sequence), probe DCC exon 17 (5¢-ATGAGTTGGACTC-
CTCCCTTGAAC-3¢, nucleotides 2226–2250), and probe b-actin
(5¢-ACTGACTACCTCATGAAGATCCTCACCGAG-3¢,
nucleotides 597–626). Hybridization signals were detected with a
DIG Luminescent Detection Kit (Boehringer Mannheim). The
conditions used for hybridization, washing and detection were in
line with the manufacturer’s recommendations. Between each
hybridization the filter was stripped before being rehybridized
with another probe.
RT-PCR/SBH data analysis
Quantitation of hybridization signals for DCC exons 6/7 and 17,
and b-actin, respectively, was performed by densitometric analysis
using NIH Image version 1.58 software. The relative expression
level of DCC mRNA was calculated by normalization to the
hybridization signals for b-actin in each case: the value for DCC
mRNA signal was divided by that for b-actin. Based on the
average values for relative DCC transcripts in normal samples,
subdivision was into four categories as follows: negative, <10% of
average values for normal ovaries; ±, 10–50%; 1+, 50–100%; 2+,
>100%, according to the methods described by Enomoto et al
(1995), with minor modification. A loss or reduction of DCC
expression was concluded with scores of either negative or ±, and
a positive one with 1+ or 2+.
Detection of alternative splicing within DCC exon 17 was
performed as described by Reale et al (1994). Briefly, DCK2834S
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5¢ splice acceptor at exon 17 was used (60-nucleotide sequence
present) or an alternatively spliced product of 281 bp if the more 3¢
splice acceptor site was employed.
Statistics
Data for DCC and p53 immunoreactivity were statistically
analysed using the Mann–Whitney U-test, the Pearson’s correla-
tion coefficient, and the c2 test.
Survival was measured from the time of the primary operation
and survival curves were generated by the methods of Kaplan and
Meier. The log-rank test and Cox proportional hazards modelling
were performed to compare survival rates between subgroups
classified on the basis of clinicopathological data and immuno-
reactivity for DCC and p53. The cut-off for statistical significance
was defined as P < 0.05.
RESULTS
DCC protein expression
In normal ovarian tissues, weak to moderate DCC immunoreac-
tivity was observed in surface epithelial cells and stromal cells. In
mature follicles, theca cells were positive but not granulosa cells.
In addition, moderate to strong immunoreactivity was apparent in
Walthard’s nests.
Moderate to strong cytoplasmic staining for DCC was diffusely
observed in cystadenomas and LMP tumours, whereas variability
in immunointensity and positive cell distribution was revealed for
carcinomas (Figures 1 and 2).
Overall average DCC values demonstrated significant stepwise
decrease from cystadenomas through to carcinomas, in line with
the results for serous and mucinous categories (Figure 3). In
ovarian carcinomas, significant differences for DCC scores among
histological phenotypes (serous vs non-serous, P < 0.0001), histo-
logical grades (G1 vs G2 or G3), and clinical stages (FIGO stage I
vs II/III/IV, P = 0.0083) were observed. Regarding lymph node
metastasis, although higher DCC scores were found for negative
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Figure 1 DCC immunoreactivity. (A, B) Cystadenomas of serous (A) and
mucinous (B) types. Original magnification, ´200. (C, D) Low malignant
potential tumours of serous (C) and mucinous (D) types. Original






Figure 2 Semiserial sections of ovarian carcinomas of grade (G) 3 serous
(A, B), G1 mucinous (C, D), G1 endometrioid (E, F), and G2 clear cell (G, H)
types. (A, C, E, G) H&E staining. (B, D, F, H) Immunohistochemistry for DCC
protein. A negative reaction is evident in the serous carcinoma (B), while the
other tumours are variously positive. Original magnification, ´200as compared to positive cases, the difference did not reach signifi-
cance (P = 0.093) (Figure 4).
DCC mRNA analysis
RNAs obtained from all ovarian samples could be successfully
amplified using primer sets for the b-actin gene, providing a frag-
ment with a molecular weight of 446 bp.
With primer sets corresponding to DCC exons 6–7 and 17, RT-
PCR products were observed with molecular weights of 233 bp
and 341 bp, respectively, a positive correlation (r = 0.874, 
P < 0.0001) between the relative amounts of both amplicons for 
all categories being significant. An alternative spliced product of
281 bp in exon 17 was detected in only one ovarian carcinoma
(case 5), while none of non-malignant samples demonstrated such
signals (Figure 5).
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23 Number of cases
Immunoreactivity
score
A Overall B Serous type C Mucinous type
a, P < 0.0001
b, P = 0.03
c, P < 0.0001
d, P < 0.0001
e, P = 0.018
f, P < 0.0001
g, P = 0.0003
h, P = 0.0087
Figure 3 (A) Overall immunoreactivity score values for DCC in cystadenoma (Ad), low malignant potential (LMP), and carcinoma (Ca) lesions. (B) DCC


























































A Subtype B Grade C Stage
a, P < 0.0001
b, P = 0.0016
c, P = 0.0005
d, P = 0.013











f, P = 0.016
Figure 4 Relation between ovarian carcinoma type and DCC immunoreactivity scores and clinicopathological factors. S, serous type; M, mucinous type; E,
endometrioid type; C, clear cell type; G, grade; P, positive; N, negative. The data are mean ± s.d. values Data from DCC mRNA analysis of ovarian carcinomas are
summarized in Table 1. Reduction (±) or loss (–) of the expression
for either DCC exons 6/7 or 17 transcripts was observed in ten
(34.5%) of 26 carcinomas. The average DCC immunoreactivity
scores (1.3 ± 2.6, mean ± s.d.) for lesions with impaired mRNA
expression were significantly lower than those (4.6 ± 3.8) in the
non-altered group (P < 0.02). There was no association between
altered DCC mRNA levels and any of several clinicopathological
factors investigated.
p53 protein expression
Nuclear p53 staining was sporadically observed in cystadenomas,
while diffusely distributed strong immunoreactivity was revealed
in carcinomas. In LMP tumours, the immunointensity and the
distribution indicated an intermediate status. None of the normal
ovarian elements showed any immunoreaction.
The p53 positivity was significantly increased in the sequence
leading from benign to malignant lesions. In carcinomas, the
immunoreactivity was significantly related to histological
subtypes (serous vs non-serous), but there was no association with
histological grade, clinical stage, lymph node status, or DCC score
(Table 2).
Survival
To examine the relation between DCC protein expression and
survival in ovarian carcinomas, subdivision was made into two
categories of non-altered (score ³ 3) and impaired (score ≤ 2)
groups, on the basis of average values of immunohistochemical
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Table 1 Data for DCC mRNA analysis in ovarian neoplasias
No. Hist Grade Stage LN IHC mRNA (DCC/b actin)* DCC
status for p53 Exon 6/7 Exon 17 score
Carcinoma
C1 S G3 II P N 1.38 (2+) 1.14 (2+) 3
C2 S G1 III N P 1.72 (2+) 1.56 (2+) 4
C3 E G1 I NE N 1.64 (2+) 1.08 (2+) 6
C4 C G2 II P P 0.89 (1+) 0.5 (1+) 0
C5 C G3 I N N 0.23 (±) 0#(–) 8
C6 C G2 I N N 0.78 (1+) 0.7 (1+) 0
C7 E G1 II N N 0.83 (1+) 0.73 (1+) 4
C8 M G1 I N P 0 (–) 0.19 (±)0
C10 S G1 I N ND 0.85 (1+) 1 (2+) 6
C11 S G1 III P P 0 (–) 0.22 (±)3
C12 S G3 III P P 1.23 (2+) 0.87 (1+) 3
C13 S G3 III NE P 1.06 (2+) 0.84 (1+) 0
C14 C G1 II N N 0.81 (1+) 0.75 (1+) 6
C15 M G3 III P N 0 (–) 0 (–) 0
C16 S G1 III NE P 0.24 (±) 0.52 (1+) 0
C17 S G1 II NE P 0.16 (±) 0.58 (1+) 0
C18 S G2 II N P 1.22 (2+) 1.52 (2+) 4
C19 S G3 IV NE N 1.48 (2+) 2 (2+) 2
C20 C G3 I N P 1 (2+) 0.93 (2+) 12
C21 M G2 III NE ND 0.14 (±) 0 (–) 0
C22 S G2 III NE N 0.38 (±) 0.83 (1+) 2
C23 S G2 II NE P 1.33 (2+) 1.46 (2+) 0
C24 C G1 I N N 0 (–) 0 (–) 0
C25 M G1 I N P 0.5 (1+) 0.71 (1+) 12
C26 M G1 I N ND 1.33 (2+) 1.58 (2+) 8
C27 C G1 I N P 0 (–) 0 (–) 0
LMP tumours
L1 M P 0.7 (1+) 0.78 (1+) 8
L2 S N 0.93 (2+) 0.75 (1+) 8
L3 M N 1.07 (2+) 1 (2+) 12
L4 M N 0.52 (1+) 0.67 (1+) 8
L5 M N 1.32 (2+) 1.32 (2+) 12
Cystadenomas
A1 S N 0.74 (1+) 0.89 (1+) 8
A2 M N 0.91 (2+) 0.81 (1+) 12
A3 M N 0.79 (1+) 0.85 (1+) 9
A4 M N 0.94 (2+) 0.9 (1+) 12
A5 S N 1 (2+) 0.97 (2+) 8
A6 M N 1.09 (2+) 1.27 (2+) 9
A7 M N 0.75 (1+) 0.42 (±)1 2
A8 M N 1.75 (2+) 1.15 (2+) 12
Normal (n = 7) 0.9±0.3 0.9±0.4
Hist, histology; S, serous type; E, endometriod type; M, mucinous type; c, Clear cell type; LMP, low malignant potential; LN meta, lymph node
metastasis; IHC, immunohistochemistry; P, positive; N, negative; ND, not done; *, relative intensity and score of DCC mRNA; #, alternatively
spliced product.DCC scores (4.2 ± 4.0) and the results of mRNA analysis of
ovarian carcinomas. As shown in Table 3, the results of univariate
analysis for prognostic markers by log-rank test in overall survival
times revealed prognostic significance for the FIGO stage, lymph
node status and DCC score in p53 negative group. On multivariate
analysis, however, these parameters did not retain statistical signi-
ficance (data not shown).
DISCUSSION
Little is known about the role of DCC gene in regulation of normal
cell growth or differentiation. Given several similarities between
DCC and members of the N-CAM family, it is speculated that
DCC may contribute to cell–cell or cell–extracellular matrix inter-
action during cellular differentiation and development (Hedrick 
et al, 1994). Chuong et al (1994) have considered that DCC is
required to maintain the basal cell status, proliferating but under
control, ready to respond to differentiating signals. Keino-Masu et
al (1996) have proposed that DCC is a receptor or a component of
a receptor that mediates the effects of netrin-1 on commissural
axons. In this study, certain levels of DCC mRNAs and proteins
were detected in normal ovarian tissues, suggesting that DCC may
also play some role in controlling differentiation of some compo-
nents in normal ovary.
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Table 2 p53 expression in benign, premalignant and malignant ovarian
neoplasias
n p53 immunopositivity P-value
Cystadenoma 40 1 (2.5%)
LMP tumour 36 11 (30.6%)
Ovarian carcinoma 124 57 (46.0%) <0.0001
Subtype
Serous 51 36 (70.6%)
Non-serous 73 17 (23.3%) <0.0001
LMP, low malignant potential.
Table 3 Univariate analysis of prognostic factors for ovarian carcinomas
Log-rank
Factor Category n c2 P-value
Subtype Serous 41 1.41 0.23
Non-serous 52
Grade G1 55 0.83 0.36
G2/G3 51
FIGO stage Stage I 38 5.49 0.02
Stage II/III/IV 68
Lymph node Positive 18 9.33 0.002
metastasis Negative 46
p53 status Positive 47 0.17 0.68
Negative 58
DCC score ³3 63 1.4 0.29
2³ 43
p53 (+) DCC score ³3 26 0.34 0.56
category DCC score 2³ 21
p53 (–) DCC score ³3 36 4.13 0.04









123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6







Figure 5 RT-PCR/Southern blot hybridization assay for DCC and b-actin in ovarian carcinomas (A) and non-malignant ovarian samples, including normal,
benign, and premalignant lesions (B). (A) Case 5 (lane 5) shows an alternative spliced product in DCC exon 17 (indicated by arrow). (B) Lanes 1–5, low
malignant potential tumours; lanes 6–13, cystadenomas; lanes 14 to 20, normal ovarian samples. Case numbers correspond to those in Table 1It has been considered that ovarian epithelial carcinomas
develop from the surface epithelium or inclusion cysts directly (de
novo) or from pre-existing benign epithelial lesions (Bell and
Scully, 1994). LMP tumours are clearly distinguished from
ovarian carcinomas by their indolent clinical outcome and delayed
recurrence (DiSaia and Creasman, 1993). Under pathological
conditions, if DCC is still present, increased cell proliferation may
be kept under control, whereas loss of DCC in these cells might
lead to loss of cell interaction, loss of proliferation control and cell
dispersion (Chuong et al, 1994). In our study, significant decrease
of DCC expression was noted from benign through to malignant
lesions, even when subdivision was into serous and mucinous
phenotypes.
In colorectal carcinomas, DCC expression has been shown to be
reduced during tumour progression from intramucosal to invasive
carcinomas, suggesting a functional role as a suppressor of metas-
tasis (Kikuchi-Yanoshita et al, 1992). Reyes-Mugica et al (1997)
have demonstrated DCC inactivation in glioma progression,
suggesting that the expression is preferentially, but not exclusively,
lost in the genetic pathway to secondary glioblastoma multiforme.
In our large series of ovarian carcinomas, the reduction or loss of
the DCC immunoreactivity was closely related to a higher histo-
logical grade and a more advanced clinical stage, indicative of a
linkage with malignant potential. Enomoto et al (1995) also
described similar findings using 22 ovarian carcinomas. With
regard to a lack of such association on mRNA analysis, one reason
may be due to the relatively small numbers of cases investigated.
It is widely accepted that overexpression of p53 proteins
detected by immunohistochemistry is usually due to an underlying
mutation of the p53 gene, although p53 expression may not always
indicate the presence of gene mutations (Maestro et al, 1992;
Wynford-Thomas, 1992). Baas et al (1994) have earlier described
that high expression (labelling index above 30%) is highly specific
(90%) to mutated cases. In this study, p53 protein accumulation
was detected in 46.0% of ovarian carcinomas with a particular
predominance in those of serous phenotype, in line with previous
studies demonstrating p53 gene mutations or overexpression in
approximately 50% of ovarian carcinomas (Klemi et al, 1995;
Reles et al, 1996; Eltabbakh et al, 1997). In contrast, our finding of
p53 overexpression in 30.6% of LMP tumours appears to be
higher as compared to previous investigations (Inoue et al, 1994;
Klemi et al, 1994). Although the exact reason for the discrepancy
with the literature is unclear, one possibility may be due to differ-
ences in the antibodies used or criteria for conclusion of positive
immunoreactivity.
Previous studies of the relation between p53 alterations and
survival of ovarian cancer cases have produced conflicting results.
Some investigators demonstrated that p53 abnormalities are
significantly associated with a poor prognosis (Klemi et al, 1995;
Herod et al, 1996), whereas others could not confirm such results
(Reles et al, 1996; Eltabbakh et al, 1997). In our cases, p53 over-
expression did not correlate with survival or any of the clinico-
pathological parameters. Although it has been reported that gastric
carcinomas with loss of heterozygosity at DCC locus frequently
exhibited p53 gene mutations, even in their early stage (Maezawa
et al, 1995), our results did not show such association.
Shibata et al (1996) have provided immunohistochemical
evidence of a prognostic significance of DCC expression in stage II
or III colorectal carcinomas. Goi et al (1998) also indicated that
colonic cancer patients with liver metastasis expressed significantly
lower levels of DCC protein than those without. In this study,
however, we could not demonstrate the prognostic values of DCC
expression in ovarian carcinomas. Although low DCC scores were
associated with unfavourable survival in the p53 negative carci-
noma group by univariate analysis, the significance of this is
unclear.
Molecular mechanisms of tumour suppressor gene inactivation
have been described at the DNA level, including point mutations,
chromosomal deletions, rearrangements and insertions. Specific
mutations in the DCC gene have not been identified, implying that
other mechanisms, such as allelic loss, aberrant splicing of tran-
scripts, and allele-specific loss of transcripts, contribute to the
inactivation of the gene (Ekstrand et al, 1995; Kong et al, 1997).
Alternative splicing sites of DCC transcripts have been demon-
strated in extracellular (exon 17) and cytoplasmic (exon 26)
domain sequences (Reale et al, 1994). In this study, an alternative
splicing transcript resulting in an extracellular domain change was
only observed in one (3.8%) carcinoma case. Although we did not
examine the cytoplasmic domain sites, our results suggested that
in ovarian carcinomas alternative splicing may play a minor role in
inactivation of DCC gene expression.
In conclusion, we have demonstrated that impairment of DCC
expression specifically occurs in ovarian carcinomas. In ovarian
carcinomas, the altered expression is closely linked with tumour
differentiation and progression.
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